-
平臺編號：bio-68508
-
國際編號：HB-12346?
-
細胞信息： AC133.1
-
規(guī)格：frozen
-
用途：ATCC原裝細胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
AC133.1
生長狀態(tài)：懸浮生長
ATCC Number：HB-12346?
數(shù)量：大量
是否是腫瘤細胞：0
物種來源：小鼠
運輸方式：凍存運輸
細胞形態(tài)：淋巴樣
免疫類型：IgG1 kappa , IgG1; kappa light chain
規(guī)格：0.5mg Designations: AC133.1
Depositors: ?Amcell Corporation
Isotype: IgG1 kappa , IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: lymphoblast B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a subset of human CD34 antigens
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with purified CD34 positive human progenitor stem cells, which had been pre-incubated with phytohemagglutinin (PHA).
Lymph node cells were fused with Sp2/0 Ag14 mouse myeloma cells.
The antibody reacts with a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood.
The subset of cells recognized by AC133 is CD34bright, and contains substantially all of the CFU-GM activity present in the CD34+ population.
This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 45095: Yin A, et al. Characterization of a human hematopoietic progenitor cell antigen. US Patent 5,843,633 dated Dec 1 1998
61362: Yin AH, et al. Human hematopoietic stem and progenitor cell antigen. US Patent 6,455,678 dated Sep 24 2002
61363: Uchida N, et al. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations. US Patent 6,468,794 dated Oct 22 2002
ATCC Number：HB-12346?
數(shù)量：大量
是否是腫瘤細胞：0
物種來源：小鼠
運輸方式：凍存運輸
細胞形態(tài)：淋巴樣
免疫類型：IgG1 kappa , IgG1; kappa light chain
規(guī)格：0.5mg Designations: AC133.1
Depositors: ?Amcell Corporation
Isotype: IgG1 kappa , IgG1; kappa light chain
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology:lymphoblast
Source: Cell Type: hybridoma: lymphoblast B lymphocyte;
Cellular Products:immunoglobulin; monoclonal antibody; against a subset of human CD34 antigens
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Comments:Animals were immunized with purified CD34 positive human progenitor stem cells, which had been pre-incubated with phytohemagglutinin (PHA).
Lymph node cells were fused with Sp2/0 Ag14 mouse myeloma cells.
The antibody reacts with a subset of hematopoietic progenitor cells derived from human bone marrow, fetal bone marrow and liver, cord blood and adult peripheral blood.
The subset of cells recognized by AC133 is CD34bright, and contains substantially all of the CFU-GM activity present in the CD34+ population.
This highly specific distribution of AC133 makes it exceptionally useful as a reagent for isolating and characterizing human hematopoietic progenitor and stem cells.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
References: 45095: Yin A, et al. Characterization of a human hematopoietic progenitor cell antigen. US Patent 5,843,633 dated Dec 1 1998
61362: Yin AH, et al. Human hematopoietic stem and progenitor cell antigen. US Patent 6,455,678 dated Sep 24 2002
61363: Uchida N, et al. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations. US Patent 6,468,794 dated Oct 22 2002
